Press Releases

June 15, 2017Peloton Therapeutics Launches Ubiquitin Ligase Research Platform
May 11, 2017Peloton Therapeutics Initiates Patient Dosing in Phase 2 Study of PT2385 for von Hippel-Lindau Disease-associated Kidney Cancer
April 3, 2017Peloton Therapeutics Appoints Mohammad Hirmand, M.D., as Chief Medical Officer
March 14, 2017Peloton Therapeutics Completes $22.2 Million Private Financing
December 15, 2016Peloton Therapeutics Doses First Patient with Solid Tumors with Follow-On Hypoxia-Inducible Factor 2α (HIF-2α) Antagonist
September 15, 2016Peloton Therapeutics Completes $52.4 Million Private Financing
September 12, 2016Peloton Therapeutics, Inc. Announces Publication of Data from Its First-in-Class HIF-2α Antagonist in Kidney Cancer in the Journal Cancer Research
September 6, 2016Peloton Therapeutics, Inc. Announces Dual Publications of HIF-2α Antagonism in Kidney Cancer in the Journal Nature
June 6, 2016Peloton Therapeutics, Inc. Presents Clinical Data on First-in-Class Oral HIF-2α Inhibitor in Patients with Advanced Kidney Cancer at 2016 ASCO Annual Meeting
April 19, 2016Peloton Therapeutics, Inc. Presents Positive Preclinical Data on First HIF-2α Inhibitor in Combination with Immuno-oncology Agents at 2016 AACR Annual Meeting
April 19, 2015Peloton Therapeutics, Inc. Presents Promising Data on First Inhibitor of HIF-2α for Renal Cell Carcinoma at 2015 AACR Annual Meeting

Information of Interest
AACR-NCI-EORTC 2017 and 16th International Kidney Cancer SymposiumPT2977, a Novel HIF-2a Antagonist, Has Potent Anti-Tumor Activity and Remodels the Immunosuppressive Tumor Microenvironment in Clear Cell Renal Cell Cancer
ASCO GU 2017W. Marston Linehan, MD, on Renal Cell Carcinoma: Genetic Predisposition
Cancer ResearchA Small-Molecule Antagonist of HIF2α Is Efficacious in Preclinical Models of Renal Cell Carcinoma
NatureOn-target efficacy of a HIF2α antagonist in preclinical kidney cancer models
NatureTargeting renal cell carcinoma with a HIF-2 antagonist
2016 Albert Lasker Basic Medical Research Award2016 Albert Lasker Basic Medical Research Award Features HIF
12th International VHL Medical SymposiumPotent, Selective, Orally Bioavailable, First-In-Class HIF-2α Antagonist (see Page 4)
12th International VHL Medical SymposiumPT2385: HIF-2α Antagonist for the Treatment of VHL Mutant ccRCC
Oncology Times ArticlePhase I Trial of HIF2-α inhibitor Reports No Dose-Limiting Toxicity
ASCO 2016A phase I dose escalation trial of PT2385, a first-in-class oral HIF-2a inhibitor, in patients with advanced clear cell renal cell carcinoma
AACR 2016PT2385, a Novel HIF-2α Antagonist, Combines with Checkpoint Inhibitor Antibodies
to Inhibit Tumor Growth in Preclinical Models by Modulating Myeloid Cells and Enhancing T Cell Infiltration
AACR 2015PT2385: First-In-Class HIF-2α Antagonist for the Treatment of Renal Cell Carcinoma